GSK has selected clinical trial software and tech firm Medable to work on its roster of decentralized and hybrid studies.
The four-year enterprise contract – financial terms of which were not made public – will see Medable provide GlaxoSmithKline (GSK) with its range of decentralized clinical trial technologies – including its eConsent, TeleVisit, and eCOA systems.
The deal is a major win for Medable according to CEO Michelle Longmire, who framed it as part of a wider trend of modernization sweeping the clinical trial sector.
“GSK has been a leader in innovative science for decades and is taking yet another transformational step forward by leveraging a modern, patient-centric model to conduct clinical trials with Medable. It's incredibly exciting, and we are looking forward to helping millions of patients together.”
Medable claims to have deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally.
It also says that some customers have seen 200 percent faster enrollment and 50 percent cost reductions as a result of using decentralized trial technologies.
Diversity
The deal could also help GSK ensure its trials are more representative. Earlier this year Palo Alto, California-based Medable partnered with pharmacy chain CVS to “expand clinical trial access and engagement for patients.”
The idea is to combine Medable’s software platform with CVS’s MinuteClinic businesses to allow patients to take part in Phase III and IV clinical trials more easily.
And increased diversity in its drug study programs is a major aim according to GSK, which wants 75% of its interventional clinical trials to have a clear demographic plan aligned with disease epidemiology by the end of the year.
The deal also comes a few months after Medable partnered with medical devices firm Withings Health Solutions.
DepositPhotos/j.dudzinski